Collaborated with Tencent (Stock Code: 00700) to Establish an AI-Powered Prediction Platform for Tumor Neoantigen Analysis

Source: Date: 2024-02-15 Views:

On February 15, 2024, we partnered with Tencent (Stock Code: 00700) to establish an AI-powered prediction platform for tumor neoantigen analysis. Leveraging artificial intelligence, the platform enables more precise identification and screening of immunogenic neoantigens. It has already been successfully applied in the development of our cancer vaccines, adoptive cell therapies, and antibody products.

Tag(s):

Previous Article: APAC Pharmaceuticals (HK) Co., Ltd. Announces the Establishment of Yancheng Biotechnology Focused on Innovative Drug Development

Next Article: Founder Mr. Cui Qi and Dr. Qiao Ying Attended the 2024 World Life Science Technology Conference and the Engineering Science Symposium of the Chinese Academy of Engineering

Top News

1APAC Pharmaceuticals (HK) Co., Ltd. Announces the Establishment of Yancheng Biotechnology Focused on Innovative Drug Development 2Dr. Qiao Ying, Co-Founder of APAC Pharmaceuticals (HK) Co., Ltd., Wins First Prize at the 9th “Contribution Award for the Chinese Diaspora” Presented by the All-China Federation of Returned Overseas Chinese 3APAC Pharmaceutical (HK) Co., Ltd., Established 4Joint Project Development with Dr. He Zhonggui, a Specially Appointed Professor under the Changjiang Scholars Award Program 5Founder Mr. Cui Qi and Dr. Qiao Ying Attended the 2024 World Life Science Technology Conference and the Engineering Science Symposium of the Chinese Academy of Engineering 6Chinese Subsidiary “Yancheng Biotech” Recognized as a Pre-IPO Candidate 7Yancheng Biotechnology Secures Patent for “Preparation Method of Hypoxilin Analogues” 8Collaborated with Tencent (Stock Code: 00700) to Establish an AI-Powered Prediction Platform for Tumor Neoantigen Analysis 9Academician Li Lanjuan of the Chinese Academy of Engineering Visits Yancheng Biotechnology for On-Site Guidance

Trending Tag(s)